Stock Ticker

  • Loading stock data...

CarpX™ Of PAVmed Inc (NASDAQ:PAVMU) Receives Recognition As An Outstanding Innovation

The stock of PAVmed Inc (NASDAQ:PAVMU) closed at $14.50 gaining 5.45% in yesterday’s trading session. PAVmed takes great pride in the fact that CarpX™ got one of the top four slots awarded by the Technology Innovation category of the 2017 Fierce Innovation Awards.

PAVmed’s Chairman and Chief Executive Officer, Lishan Aklog opined, “PAVmed is honored to have been recognized for technology innovation by one of the leading voices in the life sciences industry. I would like to thank Fierce Life Sciences and its independent panel of judges for choosing to showcase our CarpX device as an example of outstanding innovation.”

According to him, the honor in a major way validated the firm’s long-term conviction that indeed CarpX would move quite a long way towards revolutionizing the treatment of carpal tunnel syndrome. That is one of the most prevalent conditions that have over the years imposed tremendous clinical and economic burden on people around the globe.

The Co-Director of Plastic Surgery at the Center for Dermatology and Plastic Surgery in Gilbert, David A. Kelly said that it had not caught him by surprise that PAVmed’s innovative CarpX device was now receiving recognition from the industry leaders. He exuded great confidence in asserting that CarpX was going turn out to be a game-changer towards the treatment of carpal tunnel syndrome.

It is a product that is going to serve patients with a much less invasive option as well as with a shorter recovery duration which is a major contrast to the traditional open carpal tunnel surgery. He proceeded to say that he was looking forward to that moment that he would be able to offer the top end innovation to all patients that were struggling with the carpal tunnel syndrome.

Carpal tunnel syndrome happens to be a very severe form of cumulative trauma disorder and has been very common in the recent times.

It hasn’t been an easy road for the company to get to where it is at the moment, deserving such great honors. PAVmed has toiled over the years to reach the great success it is witnessing at the moment.

Published by Flavia Carruth

Hi, I am Flavia and have done my MBA with finance as specialization and a Bachelor in Economics with 4 years of experience as Financial Analyst in leading Software Firm. I have passion for article writing, report making and stock market Analysis.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts